Sun Pharma expects high-single-digit growth in its consolidated topline in FY24, driven by strong performance in all business verticals, according to its MD Dilip Shanghvi. The company will focus on sustainable and profitable business growth, cost efficiency, supply chain continuity, and investment in IT for secure systems, business operations, and digital transformation.
